KYMR – Kymera Therapeutics, Inc.
Float Short %
13.91
Margin Of Safety %
Put/Call OI Ratio
0.39
EPS Next Q Diff
0.09
EPS Last/This Y
-0.48
EPS This/Next Y
-0.18
Price
87.43
Target Price
116.71
Analyst Recom
1.25
Performance Q
35.9
Upside
-153.5%
Beta
2.22
Ticker: KYMR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | KYMR | 69.93 | 0.77 | 0.40 | 1478 |
| 2026-01-26 | KYMR | 71.13 | 0.77 | 0.25 | 1484 |
| 2026-01-27 | KYMR | 72.14 | 0.77 | 2.00 | 1488 |
| 2026-01-28 | KYMR | 71.19 | 0.77 | 2.00 | 1488 |
| 2026-01-29 | KYMR | 73.87 | 0.77 | 0.00 | 1489 |
| 2026-01-30 | KYMR | 72.75 | 0.48 | 2.00 | 1997 |
| 2026-02-02 | KYMR | 75.65 | 0.48 | 0.28 | 1998 |
| 2026-02-03 | KYMR | 77.32 | 0.47 | 0.20 | 2080 |
| 2026-02-04 | KYMR | 77.71 | 0.46 | 10.00 | 2203 |
| 2026-02-05 | KYMR | 75.95 | 0.47 | 0.00 | 2224 |
| 2026-02-06 | KYMR | 79.58 | 0.45 | 0.00 | 2289 |
| 2026-02-09 | KYMR | 79.14 | 0.42 | 0.07 | 2399 |
| 2026-02-10 | KYMR | 79.55 | 0.42 | 0.00 | 2413 |
| 2026-02-11 | KYMR | 82.36 | 0.41 | 0.02 | 2452 |
| 2026-02-12 | KYMR | 84.17 | 0.37 | 0.21 | 2754 |
| 2026-02-13 | KYMR | 82.38 | 0.36 | 2.63 | 2977 |
| 2026-02-17 | KYMR | 84.84 | 0.37 | 2.26 | 2992 |
| 2026-02-18 | KYMR | 85.2 | 0.39 | 5.64 | 3022 |
| 2026-02-19 | KYMR | 86.46 | 0.39 | 0.00 | 3026 |
| 2026-02-20 | KYMR | 87.43 | 0.39 | 0.74 | 3025 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | KYMR | 69.91 | 11.9 | -8.3 | -3.46 |
| 2026-01-26 | KYMR | 71.07 | 11.9 | -27.3 | -3.46 |
| 2026-01-27 | KYMR | 72.14 | 11.9 | -26.9 | -3.46 |
| 2026-01-28 | KYMR | 71.19 | 11.9 | -17.1 | -3.46 |
| 2026-01-29 | KYMR | 73.84 | 11.9 | -34.4 | -3.46 |
| 2026-01-30 | KYMR | 72.70 | 8.9 | -16.3 | -3.46 |
| 2026-02-02 | KYMR | 75.64 | 8.9 | -35.5 | -3.46 |
| 2026-02-03 | KYMR | 77.21 | 8.6 | -28.8 | -3.46 |
| 2026-02-04 | KYMR | 77.61 | 8.6 | -23.3 | -3.46 |
| 2026-02-05 | KYMR | 75.98 | 8.6 | -14.1 | -3.46 |
| 2026-02-06 | KYMR | 79.57 | 8.6 | -38.4 | -3.46 |
| 2026-02-09 | KYMR | 79.05 | 8.6 | -19.7 | -3.46 |
| 2026-02-10 | KYMR | 79.56 | 9.1 | -24.0 | -3.46 |
| 2026-02-11 | KYMR | 82.36 | 9.1 | -33.8 | -3.46 |
| 2026-02-12 | KYMR | 84.16 | 9.1 | -29.1 | -3.46 |
| 2026-02-13 | KYMR | 82.36 | 9.1 | -15.0 | -3.46 |
| 2026-02-17 | KYMR | 84.84 | 11.5 | -31.7 | -3.46 |
| 2026-02-18 | KYMR | 85.09 | 11.5 | -22.7 | -3.46 |
| 2026-02-19 | KYMR | 86.52 | 11.5 | - | -3.46 |
| 2026-02-20 | KYMR | 87.43 | 11.5 | - | -3.46 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | KYMR | 12.54 | 6.32 | 11.87 |
| 2026-01-26 | KYMR | 12.54 | 6.16 | 11.87 |
| 2026-01-27 | KYMR | 12.54 | 6.16 | 11.87 |
| 2026-01-28 | KYMR | 12.54 | 6.16 | 12.94 |
| 2026-01-29 | KYMR | 12.54 | 6.16 | 12.94 |
| 2026-01-30 | KYMR | 12.54 | 6.16 | 12.94 |
| 2026-02-02 | KYMR | 12.54 | 6.13 | 12.94 |
| 2026-02-03 | KYMR | 12.54 | 6.13 | 12.94 |
| 2026-02-04 | KYMR | 12.54 | 6.13 | 12.94 |
| 2026-02-05 | KYMR | 12.54 | 6.13 | 12.94 |
| 2026-02-06 | KYMR | 12.54 | 6.13 | 12.94 |
| 2026-02-09 | KYMR | 12.54 | 6.31 | 12.94 |
| 2026-02-10 | KYMR | 12.54 | 6.31 | 12.94 |
| 2026-02-11 | KYMR | 12.54 | 6.31 | 13.99 |
| 2026-02-12 | KYMR | 12.54 | 6.31 | 13.90 |
| 2026-02-13 | KYMR | 13.08 | 6.31 | 13.90 |
| 2026-02-17 | KYMR | 13.08 | 8.22 | 13.91 |
| 2026-02-18 | KYMR | 13.02 | 8.22 | 13.91 |
| 2026-02-19 | KYMR | 13.02 | 8.22 | 13.91 |
| 2026-02-20 | KYMR | 13.02 | 8.22 | 13.91 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.94
Avg. EPS Est. Current Quarter
-0.78
Avg. EPS Est. Next Quarter
-0.85
Insider Transactions
13.02
Institutional Transactions
8.22
Beta
2.22
Average Sales Estimate Current Quarter
14
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
26
Growth Score
25
Sentiment Score
80
Actual DrawDown %
15.1
Max Drawdown 5-Year %
-83.5
Target Price
116.71
P/E
Forward P/E
PEG
P/S
157.79
P/B
6.63
P/Free Cash Flow
EPS
-3.6
Average EPS Est. Cur. Y
-3.46
EPS Next Y. (Est.)
-3.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-674.81
Relative Volume
1.06
Return on Equity vs Sector %
-60.2
Return on Equity vs Industry %
-42.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Kymera Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 225
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading